Multiple paragangliomas associated with polycythemia Advocacy Hub | UniteRare

At a Glance

Live from database

💊

1FDA treatments

💰

1Open funds

Regulatory Watchboard

1 event

Mar 2022Hyftor: FDA approved

treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Hyftor

Nobelpharma America, LLC

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Hyftor

(SIROLIMUS)Orphan drug

Nobelpharma America, LLC

mTOR Inhibitor Immunosuppressant [EPC]

12.1 Mechanism of Action The mechanism of action of sirolimus in the treatment of angiofibroma associated with tuberous sclerosis is unknown. Tuberous...

Approved Mar 2022FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Multiple paragangliomas associated with polycythemia.
Search all trials →

Search clinical trials for Multiple paragangliomas associated with polycythemia →

Recent News & Research

No recent news articles indexed yet for Multiple paragangliomas associated with polycythemia.
Search PubMed for Multiple paragangliomas associated with polycythemia →

Browse all Multiple paragangliomas associated with polycythemia news →

Specialist Network

No specialists currently listed for Multiple paragangliomas associated with polycythemia.

View all Multiple paragangliomas associated with polycythemia specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰